Science and Research

DeLLphi-305: A Phase 3, Open-label, Multicen-ter, Randomized Study of Tarlatamab in Combi-nation With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Dur-valumab

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Study details
Study-ID: NCT06211036, 2023-505989-29
Study-ID: NCT06211036, 2023-505989-29
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, TLRC
DZL Participating Sites: ARCN, TLRC
Start Date: 05.06.2024
Completion Date: 30.09.2028
Status: Active / not recruiting
Status: Active / not recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.